Patents by Inventor Svante H. Hermodsson

Svante H. Hermodsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6893633
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: May 17, 2005
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Patent number: 6821510
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: November 23, 2004
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Patent number: 6790440
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: September 14, 2004
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Publication number: 20020182174
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 30, 2002
    Publication date: December 5, 2002
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Publication number: 20020182175
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 30, 2002
    Publication date: December 5, 2002
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Publication number: 20020182177
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 30, 2002
    Publication date: December 5, 2002
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Publication number: 20020182176
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 30, 2002
    Publication date: December 5, 2002
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Publication number: 20020094323
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: October 9, 2001
    Publication date: July 18, 2002
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Patent number: 5348739
    Abstract: A method of inhibiting the development of malignant tumors and the formation of metastases of malignant tumor cells in a subject carrying the comprises administering to the subject IL-2 and an agent selected from the group consisting of histamine, a histamine structural analogs having H.sub.2 -receptor activities, an endogenous histamine releasing preparation, and a non-histamine derivative H.sub.2 -receptor agonist; the agent and the IL-2 being administered in amounts and for a time effective to attain the desired effect. A method of increasing the anti-tumor cell effect of IL-2 in a subject comprises co-administering to the subject IL-2 and an agent such as histamine, histamine structural analogs having H.sub.2 -receptor activities, endogenous histamine releasing preparations or H.sub.2 -receptor agonists, the agent and the IL-2 being administered in anti-tumor effective amounts and for a period of time effective to attain the desired effect.
    Type: Grant
    Filed: March 2, 1992
    Date of Patent: September 20, 1994
    Assignee: Suntello, Inc.
    Inventors: Jan U. K. Hellstrand, Svante H. Hermodsson